Antonio DiGiandomenico | Senior Director, Head of Microbial Antibodies and Technologies, Early Vaccines and Immune Therapies
AstraZeneca

Antonio DiGiandomenico is Senior Director and Head of Microbial Antibodies and Technologies at AstraZeneca's Vaccines and Immune Therapies unit. He earned his MS in Microbiology from Duquesne University in 2001 and his PhD in Microbiology from the University of Virginia in 2005, followed by postdoctoral training in the Department of Microbiology and Immunology at Vanderbilt University. Dr. DiGiandomenico joined the Infectious Diseases team at MedImmune (now AstraZeneca) in 2009. His current research focuses on developing novel immunotherapeutics targeting antimicrobial-resistant bacteria, as well as advancing innovative vaccine and antibody delivery platforms. He has authored over 55 peer-reviewed publications and holds 6 patents.